Amubarvimab |
Catalog No.GC72389 |
Amubarvimab (BRII-196) 는 사람 IgG1 단일 클론 항체로 스파이크 단백질 수용체 결합 구조역(RBD)상의 비경쟁적 표위와 결합하며 KD는 5.88nM이다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2509447-07-6
Sample solution is provided at 25 µL, 10mM.
Amubarvimab shows specific activity against wild-type SARS-CoV-2 and no cross-reactivity against other coronaviruses[1].
Amubarvimab binds to two regions spanning amino acids 453-505 in the receptor-binding motif (RBM) and amino acids residues 403-421 in the core region of RBD[1].
Amubarvimab (10-50 mg/kg; i.p.) in combination with romlusevimab significantly decreases viral load in the lungs, and reduces lung pathology in a Syrian golden hamster model of SARS-CoV-2 infection[1].
References:
[1]. Ji Y, et, al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. Front Immunol. 2022 Sep 14;13:980435.
[2]. Hoy SM. Amubarvimab/Romlusevimab: First Approval. Drug. 2022 Aug;82(12):1327-1331.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *